Hybrid response to SARS-CoV-2 and Neisseria meningitidis C after an OMV-adjuvanted immunization in mice and their offspring.

Hybrid response to SARS-CoV-2 and Neisseria meningitidis C after an OMV-adjuvanted immunization in mice and their offspring.

Publication date: Dec 31, 2024

COVID-19, caused by SARS-CoV-2, and meningococcal disease, caused by Neisseria meningitidis, are relevant infectious diseases, preventable through vaccination. Outer membrane vesicles (OMVs), released from Gram-negative bacteria, such as N. meningitidis, present adjuvant characteristics and may confer protection against meningococcal disease. Here, we evaluated in mice the humoral and cellular immune response to different doses of receptor binding domain (RBD) of SARS-CoV-2 adjuvanted by N. meningitidis C:2a:P1. 5 OMVs and aluminum hydroxide, as a combined preparation for these pathogens. The immunization induced IgG antibodies of high avidity for RBD and OMVs, besides IgG that recognized the Omicron BA. 2 variant of SARS-CoV-2 with intermediary avidity. Cellular immunity showed IFN-γ and IL-4 secretion in response to RBD and OMV stimuli, demonstrating immunologic memory and a mixed Th1/Th2 response. Offspring presented transferred IgG of similar levels and avidity as their mothers. Humoral immunity did not point to the superiority of any RBD dose, but the group immunized with a lower antigenic dose (0. 5 μg) had the better cellular response. Overall, OMVs enhanced RBD immunogenicity and conferred an immune response directed to N. meningitidis too.

Concepts Keywords
Hybrid adjuvants
Hydroxide Adjuvants, Immunologic
Immunologic Adjuvants, Vaccine
Meningitidis Aluminum Hydroxide
Mothers Animals
Antibodies, Bacterial
Antibodies, Viral
Antibody Affinity
COVID-19
COVID-19 Vaccines
cross-reaction
Female
Immunity, Cellular
Immunity, Humoral
Immunization
Immunoglobulin G
Immunologic Memory
Meningococcal Infections
Meningococcal Vaccines
Mice
Neisseria meningitidis
Neisseria meningitidis
receptor-binding domain (RBD)
SARS-CoV-2
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Th1 Cells

Semantics

Type Source Name
disease VO immunization
disease MESH COVID-19
disease MESH meningococcal disease
disease MESH infectious diseases
disease VO vaccination
disease VO Bacteria
drug DRUGBANK Aluminum hydroxide
drug DRUGBANK Binetrakin
disease VO dose
disease VO immunized
drug DRUGBANK Tropicamide
disease IDO immune response
disease VO vaccine
disease VO Glycoprotein

Original Article

(Visited 2 times, 1 visits today)